Interestingly, patients with higher expression levels of VEGF-A, VEGFR-1, and VEGFR-2 in the tumor showed a markedly shorter survival time, compared with patients exhibiting low VEGF-A levels or only expressing one receptor type. This evidence concerns the gene VEGFA and neoplasm.